
|Articles|April 1, 2010
Hypertension drug approved for pediatric patients
Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.
Advertisement
Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.
The recommended starting dose is 10 mg once daily for patients who weigh 20 kg to less than 35 kg and 20 mg once daily for patients who weigh at least 35 kg. After 2 weeks, the dose can be increased to a maximum of 20 mg once daily in those who weigh less than 35 kg and 40 mg once daily in those who weigh at least 35 kg.
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes
2
How to recognize and when to refer for children with hidradenitis suppurativa
3
Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation
4
Supporting children with hidradenitis suppurativa beyond medical treatment, with Colleen Cotton, MD
5




